<DOC>
	<DOCNO>NCT00304421</DOCNO>
	<brief_summary>The purpose study compare effect two different drug , rabeprazole ( 20 mg ) pantoprazole ( 40 mg ) , effect amount acid produce stomach even night standard protein meal .</brief_summary>
	<brief_title>Comparison Nighttime Effects Two Different Drugs Subjects With GERD</brief_title>
	<detailed_description>Gastric acid secretion divide two phase : daytime phase nocturnal phase . Nocturnal acid reflux presumably damaging loss salivary neutralization . The present study design measure effect rabeprazole pantoprazole post-prandial nocturnal gastric acid secretion intragastric pH H. pylori-negative volunteer gastroesophageal reflux disease . These measurement use compare degree inhibition gastric acid secretion two drug .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>1 . Subjects , 1865 year age , inclusive , male female , race , willing undergo test study center . 2 . Female subject must able conceive reason surgery , radiation , 2 year past onset menopause , approve method contraception ( e.g. , IUD , oral contraceptive least one cycle , implant , double barrier method ) . Female subject childbearing potential must negative serum pregnancy test screen negative urine pregnancy test medication dispense . 3 . Subjects must negative result screen H. pylorus serology , history H. pylorus eradication . 4 . Subjects must history GERD without antacid use . 5 . Subjects must able tolerate nasogastric tube placement . 1 . History gastric surgery , fundoplication vagotomy . 2 . Pyloric stenosis Barrett 's esophagus esophageal stricture . 3 . Treatment histamine H2receptor antagonist , prostaglandin , sucralfate within 14 day enrollment study . 4 . Treatment rabeprazole , omeprazole , lansoprazole , pantoprazole , esomeprazole , prokinetic agent , bismuth subsalicylate within 30 day enrollment study . 5 . Concurrent serious systemic disorder , include renal insufficiency hepatic insufficiency . 6 . Subjects neoplasia undergoing treatment cancer ( e.g. , chemotherapy , radiation . 7 . Any condition associate poor subject compliance ( e.g. , alcohol abuse , drug abuse ) . 8 . History clinically significant abuse alcohol define ( 1 ) pattern alcohol intake consistent disruption normal function society ; ( 2 ) history , current existence indication difficulty abstain alcohol require duration present protocol ; ( 3 ) use alcohol within one day study period . 9 . Subjects receive investigational agent within previous 30 day . 10 . Inability subject return schedule visit . 11 . Subjects , opinion investigator , poor medical psychiatric risk therapy investigational drug . 12 . History hypersensitivity reaction rabeprazole , pantoprazole inactive ingredient . 13 . Any significant evidence screen endocrine , cardiovascular , and/or pulmonary disorder . 14 . Any predisposing condition might interfere absorption , distribution , metabolism , excretion drug , history abnormal bleeding tendency thrombophlebitis . 15 . History HIV , hepatitis B , hepatitis C infection . 16 . Subjects pregnant likely become pregnant course study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Gastroesophageal Reflux Disease</keyword>
	<keyword>Proton Pump Inhibitors</keyword>
	<keyword>Gastric pH</keyword>
	<keyword>Gastric Acid Secretion</keyword>
</DOC>